Clinical Edge Journal Scan

Incidence of cardiovascular events in patients with moderate-to-severe atopic dermatitis


 

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) had the highest incidence rate (IR) per 1000 person-years for major adverse cardiovascular events (MACE), followed by venous thrombotic events (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE).

Major finding: The IR per 1000 person-years for MACE, VTE, DVT, and PE were 2.6 (95% CI 2.1-3.2), 2.0 (95% CI 1.5-2.5), 1.6 (95% CI 1.2-2.1), and 0.7 (95% CI 0.5-1.0), respectively.

Study details: This retrospective cohort study included 8197 patients aged 12 years with moderate-to-severe AD.

Disclosures: This study was funded by Pfizer, Inc. Some authors declared receiving grant funding from Pfizer. Two authors declared being current or former employees and shareholders of Pfizer.

Source: Hedderson MM et al. Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: A retrospective cohort study. PLoS One. 2022;17(11):e0277469 (Nov 17). Doi: 10.1371/journal.pone.0277469

Recommended Reading

Rocatinlimab shows promise in moderate-to-severe atopic dermatitis
MDedge Dermatology
Meta-analysis supports safe use of topical calcineurin inhibitors in AD
MDedge Dermatology
Tralokinumab improves microbial dysbiosis in lesional skin in AD
MDedge Dermatology
Tralokinumab improves microbial dysbiosis in lesional skin in AD
MDedge Dermatology
Phase 3 studies confirm long-term disease control with ruxolitinib cream in atopic dermatitis
MDedge Dermatology
Early emollient application: An effective strategy for atopic dermatitis prevention in infants
MDedge Dermatology
Dupilumab is clinically effective and safe for treating pediatric atopic dermatitis in daily practice
MDedge Dermatology
High treatment flexibility with baricitinib in moderate-to-severe atopic dermatitis
MDedge Dermatology
First exposure to general anesthesia not a risk factor for atopic dermatitis in the pediatric population
MDedge Dermatology
Baricitinib a promising treatment option for difficult-to-treat atopic dermatitis in daily practice
MDedge Dermatology